This Company is Making Cardiac Exams Better
Cardiovascular diseases are responsible for more deaths each year, all around the world. Stats from the World Health Organization show that, in 2012, these diseases where the reason behind nearly a third all global deaths (31%). These numbers are a clear indication of just how serious this problem really is.
On the positive side, most cardiovascular diseases can be prevented. This prevention is closely linked to behavioral aspects, such as tobacco use, unhealthy diet and obesity, and physical inactivity, among others. But cardiovascular diseases can also be avoided with close monitoring, with a vast array of exams available.
One might think that the innovation in this field is scarce, and that the tools used in these exams do not evolve. Truthfully, this is a wrong notion, as BioSig clearly shows. This medical device company, based in Minneapolis, is developing the PURE EP system, a proprietary technology platform aiming to reinvent the electrophysiology (EP) industry.
Most of EP systems available today have limited dynamic range, meaning that small signals appear and have to be amplified. PURE EP works to collect and display this important clinical data during EP and cardiac procedures, with unparalleled quality and reliability.
All testing, carried out in prestigious institutions such as Texas Cardiac Arrhythmia Institute, Mayo Clinic, Mount Sinai and UCLA, showed that PURE EP mitigates the aforementioned problems. It consists of a surface electrocardiogram, intracardiac multichannel recording, and analysis system.
With this, PURE EP is able to provide health professionals with high-fidelity cardiac signal recordings and better overall data, thus contributing for an improved decision-making. This can then guide professionals towards the identification of health conditions.
BioSig plans to file for a 510(k) marketing clearance in the first half of 2017 and, once approved, it will reach one of the fastest growing medical device fields, thought to grow at a 12.1% a year rate to $5.5 billion by 2019.